DOCSLIB.ORG

Charles Edward Schwartz JC Self Research

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Charles Edward Schwartz JC Self Research NAME: Charles Edward Schwartz ADDRESS: (Office): JC Self Research Institute Greenwood Genetic Center 113 Gregor Mendel Circle Greenwood, SC 29646 Colgate University (Hamilton, NY) EDUCATION: Major - Chemistry B.A. - 1970 Oklahoma State University (Stillwater, OK) Major - Biochemistry M.S. - 1972 Vanderbilt University (Nashville, TN) Major - Biochemistry Ph.D. - 1978 POSITIONS: Research Assistant Long Island Jewish Hospital Hillside Medical Center New Hyde Park, New York 1972-1974 NCI Postdoctoral Fellow University of Vermont Department of Biochemistry Burlington, Vermont 1978-1980 Research Scientist La Jolla Cancer Research Foundation La Jolla, California 1980-1981 NIH Postdoctoral Fellow Division of Hematology/Oncology University of Utah School of Medicine Salt Lake City, Utah 1981-1983 Research Associate Department of Human Genetics University of Utah School of Medicine Salt Lake City, Utah 1983-1985 Director, Molecular Genetics Laboratory Greenwood Genetic Center Greenwood, SC 29646 July, 1985-December 1995 1 Last Updated on 02/08/16 at 10:42 AM Adjunct Associate Professor of Biological Sciences Clemson University Clemson, SC 1987-present Assistant Professor of Pediatrics University of South Carolina Columbia, SC 1987-present Adjunct Assistant Professor of Biology University of South Carolina Columbia, SC 1988-present Director, Center for Molecular Studies J.C. Self Research Institute Greenwood Genetic Center Greenwood, South Carolina 29646 January 1996-present Adjunct Professor, Department of Genetics and Biochemistry Clemson University Clemson, SC 2001-present Director, J.C. Self Research Institute Greenwood Genetic Center Greenwood, South Carolina 29646 January 2004-present Clinical Rotation Faculty Master of Science Genetic Counseling Program Department of Obstetrics and Gynecology School of Medicine University of South Carolina Columbia, SC July 2004-present PROFESSIONAL ACTIVITY/ Member COMMITTEES International Union Against Cancer Committee on the Immunodiagnosis of Cancer 1983-1986 Co-Chairman DNA Committee SERGG 1988-1990 Chairman DNA Committee SERGG 1990-1992 Member, OCLG Steering Committee DNA Section 1991-1993 2 Last Updated on 02/08/16 at 10:42 AM American Board of Medical Genetics Director, Clinical Molecular Genetics January 2006-present Treasurer January 2007-December 2007 President Elect January 2008-December 2008 President January 2009-December 2009 APPOINTMENTS: Visiting Research Scientist Institut de Pathologie Moleculaire Inserm U. 129 Hopital Cochin Paris 75014 France March 1 - June 1 1985 Visiting Lecturer Human Genetics Universidad Central del Caribe Escuela de Medicine Cayey, Puerto Rico December 1987 Visiting Scientist Departmento de Zootecnia ESALQ-USP Piracicaba, Brazil July- August, 1996 Visiting Senior Scientist INSERM U491 Hopital La Timone Marseille, France July 1998–June 1999 CERTIFICATION: Diplomate, American Board of Medical Genetics (Molecular Genetics) 1993 PROFESSIONAL SOCIETIES: Phi Society New York Academy of Science International Society for Oncodevelopmental Biology and Medicine American Society of Human Genetics European Society of Human Genetics International Mammalian Genome Society Nov. 1993 Fellow, American College of Medical Genetics AWARDS: Professional of the Year, SC Chapter of the American Association on Mental Retardation, November 8, 2002 Robert Guthrie Award for Advances in Biochemical and Molecular Genetics, American Association of Mental Retardation, May 23, 2003. 3 Last Updated on 02/08/16 at 10:42 AM BOOKS: 1. Schwartz CE, Norton L, McKay K, Krall J, Kay D, Lynch RE: Does the content of superoxide dismutase in E. Coli affect resistance to killing by neutrophils? In OXY Radicals and Their Scavenger Systems (RA Greenwald and G Cohen, eds.), Cellular and Medical Aspects Vol II: 86- 91, 1983. 2. Schwartz CE, Skolnick MH: Mapping the human genome using restriction fragment length polymorphism (RFLPs). In Genetica Molecula, Instituto Ciencias del Hombre, Madrid, Chapter 8, pp. 151-166, 1985. 3. Schwartz CE, Brown AM, Der Kaloustian VM, McGill JJ, Saul RA: DNA finger-printing: The utilization of minisatellite probes to detect a somatic mutation in the Proteus syndrome. DNA Fingerprinting: Approaches and Applications, (T Burke, G Dolf, AJ Jeffreys, R Wolff, eds), pp. 95- 105, 1991. 4. Schwartz CE, Lubs HA, Arena JF, Stevenson RE: Evidence that distinct regions on the X chromosome have a high concentration of genes causing mental retardation in Biological Psychiatry, Vol 2, (G. Racagni et al, editors), pp. 481-484, 1991. 5. Stevenson RE, Schwartz CE, Schroer RJ: X-linked mental retardation. 2000. 6. Schwartz C: Renpenning Syndrome. The Gale Encyclopedia of Genetic Disorders. Stacey L. Blachford, Editor. Farmington Hills, Mich.: Gale Group, 2001. 7. Schwartz C: Sutherland-Haan Syndrome. The Gale Encyclopedia of Genetic Disorders. Stacey L. Blachford, Editor. Farmington Hills, Mich.: Gale Group, 2001. 8. Schwartz C: Allan-Herndon-Dudley Syndrome. Orphanet Encyclopedia, May 2001: http://orphanet.infobiogen.fr/data/patho/uk-allan.html. 9. Schwartz CE, Stevenson RE: The MCT8 thyroid hormone transporter and Allan-Herndon-Dudley syndrome. Best Practice & Research: Clinical Endocrinology & Metabolism, 2007: 21:307-321. 10. Schwartz CE: PQBP1 and the Renpenning, Sutherland-Haan, Golabi-Ito-Hall, and Hamel Cerebropalatocardiac and XLMR Syndromes and Nonsyndromic XLMR. Inborn Errors of Development, Second Edition, edited by Charles J. Epstein, Robert P. Erickson, and Anthony Wynshaw-Boris, 2008, pp. 1177-1185. 11. Stevenson RE, Schwartz CE, Rogers RC: Atlas of X-Linked Intellectual Disability Syndromes. 2012. PUBLICATIONS: 1. Greenwald RA and Schwartz C: Complex formation between lysozyme and cartilage proteoglycans. Biochemica et biophysica. Acta 359:66-72, 1974. 2. Greenwald RA, Schwartz CE, Cantor JO: Interaction of cartilage proteoglycans with collagen- substituted agarose gels. Biochem J 145:601-605, 1975. 4 Last Updated on 02/08/16 at 10:42 AM 3. Greenwald RA, Cantor JO, Schwartz CE, Josephson AS: Effects of acute cartilaginous injury on serum and cartilage lysozyme levels. Arthritis and Rheumatism18:139-144, 1975. 4. Schwartz CE, Hellerqvist CG, Cunningham LW: A collagenous component of the microexudate carpet secreted by attaching human fibroblasts. Ann NY Acad Science 312:450-452, 1978. 5. Schwartz CE, Hoffman L, Hellerqvist CG, Cunningham LW: Scanning electron microscope visualization of a microexudate prepared by the release of cells by urea. Exp Cell Res 118:427- 430, 1979. 6. Commer P, Schwartz C, Tracy S, Tamaoki T, Chiu JF: Dexamethasone inhibits alpha-fetoprotein gene expression in developing mouse liver. Biochem Biophys Res Commun 89:1294-1299, 1979. 7. Schwartz CE, Hellerqvist CG, Cunningham LW: Attaching human fibroblasts secrete a type I procollagen rich in 3-hydroxyproline. Biochem Biophys Res Commun 90:240-246, 1979. 8. Chiu JF, Massari RJ, Schwartz CE, Meisler NT, Thomassi JW: Hormonal modulation of alpha- fetoprotein gene expression in newborn rat livers. Nucleic Acid Res 9:6917-6933, 1981. 9. Oldberg A, Schwartz C, Rusolahti E: Isolation and partial characterization of a rat hepatoma heparan sulfate proteoglycan. Arch Biochem Biophys 216:400-406, 1982. 10. Schwartz CE, Gabrzelak T, Smith CJ, Taylor JM, Chiu JF: The expression of alpha-fetoprotein and albumin genes in rat liver during chemical carcinogenesis. Biochem Biophys Res Commun 107:239-245, 1982. 11. Schwartz CE, Burkhardt AL, Huand DP, Chiu JF: The effects of dexamethasone on a alpha- fetoprotein and albumin synthesis in cultured hematoma 7777 cells. Bioscience Reports 2:777- 784, 1982. 12. Jacobson JA, Schwartz CE, Marshall HW, Conti M, Burke JP: Fever, chills and hypotension following cardiac catherization with single- and multiple-use disposable catheters. Cathet Cardiovasc Diagn 9:39-46, 1983. 13. Chiu JF, Huang DP, Burkhardt AL, Cote G, Schwartz CE: The alteration of gene expression in rat liver during chemical carcinogenesis. Arch Biochem Biophys 222:310-320, 1983. 14. Schwartz CE, Ruoslahti E: Concurrent modulation of cell surface fibronectin and adhesion to fibronectin in hepatoma cells. Exp Cell Res 143:456-461, 1983. 15. Schwartz CE, Krall J, Norton L, McKay K, Kay D, Lynch RE: Catalase and superoxide dismutase in Escherichia coli: Roles in resistance to killing by neutrophils. J Biol Chem 258:6277-6281, 1983. 16. Huang DP, Schwartz CE, Chiu JF, Cook JR: Dexamethasone inhibition of rat hepatoma growth and alpha-fetoprotein synthesis. Cancer Res 44:2976-2980, 1984. 17. Bock SC, Harris JF, Schwartz CE, Ward JH, Hershgold H, Skolnick MH: Hereditary thrombosis in a Utah kindred is caused by a dysfunctional antithrombin III gene. Am J Hum Genet 37:32-41, 1985. 18. Cook JR, Schwartz CE, Fausel ED, Chiu JF: Effect of sodium butyrate on alpha-fetoprotein gene expression in rat hepatoma cells in vitro. Cancer Res 45:3215-3219, 1985. 5 Last Updated on 02/08/16 at 10:42 AM 19. Taggard RT, Samloff IM, Graham A, Cass C, Raffel LJ, Rotter JJ, Petersen, Skolnick MH, Schwartz CE, Bell GI: Relationships between the human pepsinogen DNA and protein polymorphisms. Am J Hum Genet 38:848-854, 1986. 20. Dietz JN, Robbins T, Cannon LA, Schwartz CE, Carey JC, Johnson JP, Kivlin J, Skolnic MH: Linkage analysis of Von Recklinghausen neurofibromatosis: Chromosomes 4 and 19. Genet Epidemiol 3:313-321, 1986. 21. Schwartz CE, McNally E, Leinwand L, Skolnick MH: A polymorphic human myosin heavy chain locus is linked to an anonymous single copy locus (D17S1) at 17p13. Cytogenet Cell Genet 43:117-120, 1986. 22. Willard
Load more

Recommended publications
  • CRASH Syndrome: Clinical Spectrum Vance Lemmon0 Guy Van Campa of Corpus Callosum Hypoplasia, Lieve Vitsa Retardation, Adducted Thumbs, Paul Couckea Patrick J
    Review 1608178 Eur J Hum Genet 1995;3:273-284 Erik Fransen3' CRASH Syndrome: Clinical Spectrum Vance Lemmon0 Guy Van Campa of Corpus Callosum Hypoplasia, Lieve Vitsa Retardation, Adducted Thumbs, Paul Couckea Patrick J. Willemsa Spastic Paraparesis and a Department of Medical Genetics, Hydrocephalus Due to Mutations in University of Antwerp, Belgium; One Single Gene, L1 b Case Western Reserve University, Cleveland, Ohio, USA Keywords Abstract X-linked disorder LI is a neuronal cell adhesion molecule with important func­ Mental retardation tions in the development of the nervous system. The gene Hydrocephalus encoding LI is located near the telomere of the long arm of the MASA syndrome X chromosome in Xq28. We review here the evidence that Adducted thumbs several X-linked mental retardation syndromes including X- Corpus callosum agenesis linked hydrocephalus (HSAS), MASA syndrome, X-linked Spastic paraplegia complicated spastic paraparesis (SPI) and X-linked corpus LI callosum agenesis (ACC) are all due to mutations in the LI CRASH gene. The inter- and intrafamilial variability in families with Mutation analysis an LI mutation is very wide, and patients with HSAS, MASA, SPI and ACC can be present within the same family. There­ fore, we propose here to refer to this clinical syndrome with the acronym CRASH, for Corpus callosum hypoplasia, Retar­ dation, Adducted thumbs, Spastic paraplegia and Hydroceph­ alus. Clinical Aspects for Hydrocephalus due to Stenosis of the Aqueduct of Sylvius. This designation was X-Linked Hydrocephalus based upon the presence of aqueductal steno­ X-linked hydrocephalus (MIM No. sis in many HSAS patients [1]. However, later 307000) was originally described by Bickers studies reported several HSAS patients with and Adams in 1949.
    [Show full text]
  • The Mutability and Repair of DNA
    B.Sc (Hons) Microbiology (CBCS Structure) C-7: Molecular Biology Unit 2: Replication of DNA The Mutability and Repair of DNA Dr. Rakesh Kumar Gupta Department of Microbiology Ram Lal Anand College New Delhi - 110021 Reference – Molecular Biology of the Gene (6th Edition) by Watson et. al. Pearson education, Inc Principles of Genetics (8th Edition) by D. Peter Snustad, D. Snustad, Eldon Gardner, and Michael J. Simmons, Wiley publications Replication errors and their repair The Nature of Mutations: • Transitions: A kind of the simplest mutation which is pyrimidine-to-pyrimidine and purine-to- purine substitutions such as T to C and A to G • Transversions: The other kind of mutation which are pyrimidine-to-purine and purine-to- pyrimidine substitutions such as T to A or G and ATransitions to C or T. Transversions 8 types 4 types Synonymous substitution Non synonymous substitution • Point mutations: Mutations that alter a single nucleotide Other kinds of mutations (which cause more drastic changes in DNA): • Insertions • Deletions • Gross rearrangements of Thesechromosome mutations might be caused by insertion by transposon or by aberrant action of cellular recombination processes. Mutation • Substitution, deletion, or insertion of a base pair. • Chromosomal deletion, insertion, or rearrangement. Somatic mutations occur in somatic cells and only affect the individual in which the mutation arises. Germ-line mutations alter gametes and passed to the next generation. Mutations are quantified in two ways: 1. Mutation rate = probability of a particular type of mutation per unit time (or generation). 2. Mutation frequency = number of times a particular mutation occurs in a population of cells or individuals.
    [Show full text]
  • Genetic Causes.Pdf
    1 September 2015 Genetic causes of childhood apraxia of speech: Case‐based introduction to DNA, inheritance, and clinical management Beate Peter, Ph.D., CCC‐SLP Assistant Professor Dpt. of Speech & Hearing Science Arizona State University Adjunct Assistant Professor AG Dpt. of Communication Sciences & Disorders ATAGCT Saint Louis University T TAGCT Affiliate Assistant Professor Dpt. of Speech & Hearing Sciences University of Washington 1 Disclosure Statement Disclosure Statement Dr. Peter is co‐editor of a textbook on speech development and disorders (B. Peter & A. MacLeod, Eds., 2013), for which she may receive royalty payments. If she shares information about her ongoing research study, this may result in referrals of potential research participants. She has no financial interest or related personal interest of bias in any organization whose products or services are described, reviewed, evaluated or compared in the presentation. 2 Agenda Topic Concepts Why we should care about genetics. Case 1: A sporadic case of CAS who is missing a • Cell, nucleus, chromosomes, genes gene. Introduction to the language of genetics • From genes to proteins • CAS can result when a piece of DNA is deleted or duplicated Case 2: A multigenerational family with CAS • How the FOXP2 gene was discovered and why research in genetics of speech and language disorders is challenging • Pathways from genes to proteins to brain/muscle to speech disorder Case 3: One family's quest for answers • Interprofessional teams, genetic counselors, medical geneticists, research institutes • Early signs of CAS, parent education, early intervention • What about genetic testing? Q&A 3 “Genetic Causes of CAS: Case-Based Introduction to DNA, Inheritance and Clinical Management,” Presented by: Beate Peter, PhD, CCC-SLP, September 29, 2015, Sponsored by: CASANA 2 Why should you care about genetics? 4 If you are a parent of a child with childhood apraxia of speech … 5 When she was in preschool, He doesn’t have any friends.
    [Show full text]
  • Mutation by Dr. Ty C.M. Hoffman
    Mutation by Dr. Ty C.M. Hoffman Slide 1 Transcription features a one-to-one correspondence between DNA nucleotides in the gene and RNA nucleotides in the RNA transcript. However, the four nucleotide types used in RNA are insufficient to individually specify all twenty biological amino acids during translation. Instead, a sequence of three mRNA nucleotides (collectively called a codon) specifies a single amino acid. Since there are three nucleotide positions within a codon, and each position can be occupied by any of four types of nucleotide, there are sixty-four possible codons. This is more than enough to specify the twenty biological amino acids. Slide 2 The genetic code is universal in that all organisms (with very few exceptions) use the same code for specifying amino acids with mRNA codons. The genetic code is redundant in that more than one codon can specify the same amino acid. This is because there are more types of codons than there are types of amino acids used by organisms. The genetic code is not ambiguous, however, because each codon always specifies the same amino acid. Four of the codons serve special functions. One operates as a start codon (signaling initiation of translation), and three codons operate as stop codons (signaling the termination of translation). Slide 3 Mutation is a random change in the DNA sequence of nucleotides. Mutation can be purely accidental (by a mistake made during DNA replication), or mutation can result from exposure of DNA to a mutagen (something that causes mutation). Mutations can be classified into two major types: • Base-pair substitutions do not change the number of nucleotides in the DNA, because one base pair is substituted for another.
    [Show full text]
  • Advances in Understanding the Genetics of Syndromes Involving Congenital Upper Limb Anomalies
    Review Article Page 1 of 10 Advances in understanding the genetics of syndromes involving congenital upper limb anomalies Liying Sun1#, Yingzhao Huang2,3,4#, Sen Zhao2,3,4, Wenyao Zhong1, Mao Lin2,3,4, Yang Guo1, Yuehan Yin1, Nan Wu2,3,4, Zhihong Wu2,3,5, Wen Tian1 1Hand Surgery Department, Beijing Jishuitan Hospital, Beijing 100035, China; 2Beijing Key Laboratory for Genetic Research of Skeletal Deformity, Beijing 100730, China; 3Medical Research Center of Orthopedics, Chinese Academy of Medical Sciences, Beijing 100730, China; 4Department of Orthopedic Surgery, 5Department of Central Laboratory, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China Contributions: (I) Conception and design: W Tian, N Wu, Z Wu, S Zhong; (II) Administrative support: All authors; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: Y Huang; (V) Data analysis and interpretation: L Sun; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Wen Tian. Hand Surgery Department, Beijing Jishuitan Hospital, Beijing 100035, China. Email: [email protected]. Abstract: Congenital upper limb anomalies (CULA) are a common birth defect and a significant portion of complicated syndromic anomalies have upper limb involvement. Mostly the mortality of babies with CULA can be attributed to associated anomalies. The cause of the majority of syndromic CULA was unknown until recently. Advances in genetic and genomic technologies have unraveled the genetic basis of many syndromes- associated CULA, while at the same time highlighting the extreme heterogeneity in CULA genetics. Discoveries regarding biological pathways and syndromic CULA provide insights into the limb development and bring a better understanding of the pathogenesis of CULA.
    [Show full text]
  • Hereditary Spastic Paraparesis: a Review of New Developments
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.69.2.150 on 1 August 2000. Downloaded from 150 J Neurol Neurosurg Psychiatry 2000;69:150–160 REVIEW Hereditary spastic paraparesis: a review of new developments CJ McDermott, K White, K Bushby, PJ Shaw Hereditary spastic paraparesis (HSP) or the reditary spastic paraparesis will no doubt Strümpell-Lorrain syndrome is the name given provide a more useful and relevant classifi- to a heterogeneous group of inherited disorders cation. in which the main clinical feature is progressive lower limb spasticity. Before the advent of Epidemiology molecular genetic studies into these disorders, The prevalence of HSP varies in diVerent several classifications had been proposed, studies. Such variation is probably due to a based on the mode of inheritance, the age of combination of diVering diagnostic criteria, onset of symptoms, and the presence or other- variable epidemiological methodology, and wise of additional clinical features. Families geographical factors. Some studies in which with autosomal dominant, autosomal recessive, similar criteria and methods were employed and X-linked inheritance have been described. found the prevalance of HSP/100 000 to be 2.7 in Molise Italy, 4.3 in Valle d’Aosta Italy, and 10–12 Historical aspects 2.0 in Portugal. These studies employed the In 1880 Strümpell published what is consid- diagnostic criteria suggested by Harding and ered to be the first clear description of HSP.He utilised all health institutions and various reported a family in which two brothers were health care professionals in ascertaining cases aVected by spastic paraplegia. The father was from the specific region.
    [Show full text]
  • Bio 102 Practice Problems Genetic Code and Mutation
    Bio 102 Practice Problems Genetic Code and Mutation Multiple choice: Unless otherwise directed, circle the one best answer: 1. Choose the one best answer: Beadle and Tatum mutagenized Neurospora to find strains that required arginine to live. Based on the classification of their mutants, they concluded that: A. one gene corresponds to one protein. B. DNA is the genetic material. C. "inborn errors of metabolism" were responsible for many diseases. D. DNA replication is semi-conservative. E. protein cannot be the genetic material. 2. Choose the one best answer. Which one of the following is NOT part of the definition of a gene? A. A physical unit of heredity B. Encodes a protein C. Segement of a chromosome D. Responsible for an inherited characteristic E. May be linked to other genes 3. A mutation converts an AGA codon to a TGA codon (in DNA). This mutation is a: A. Termination mutation B. Missense mutation C. Frameshift mutation D. Nonsense mutation E. Non-coding mutation 4. Beadle and Tatum performed a series of complex experiments that led to the idea that one gene encodes one enzyme. Which one of the following statements does not describe their experiments? A. They deduced the metabolic pathway for the synthesis of an amino acid. B. Many different auxotrophic mutants of Neurospora were isolated. C. Cells unable to make arginine cannot survive on minimal media. D. Some mutant cells could survive on minimal media if they were provided with citrulline or ornithine. E. Homogentisic acid accumulates and is excreted in the urine of diseased individuals. 5.
    [Show full text]
  • MASA Syndrome in Twin Brothers: Case Report of Sixteen-Year Clinical Follow Up
    Paediatr Croat. 2014;58:286-90 PRIKAZ BOLESNIKA / CASE REPORT www.paedcro.com http://dx.doi.org/10.13112/PC.2014.50 MASA syndrome in twin brothers: case report of sixteen-year clinical follow up Matilda Kovač Šižgorić1, Zlatko Sabol1, Filip Sabol2, Tonći Grmoja3, Svjetlana Bela Klancir1, Zdravka Gjergja1, Ljiljana Kipke Sabol1 MASA syndrome (OMIM 303350) is a rare X-linked recessive neurologic disorder, also called CRASH syndrome, spastic paraplegia 1 and Gareis-Mason syndrome. The acronym MASA describes four major signs: Mental retardation, Aphasia, Shuffl ing gait and Adducted thumbs. A more suitable name for this syndrome is L1 syndrome because the disorder has been associated with mutations in the neuronal cell adhesion molecule L1 (L1CAM) gene. The syndrome has severe symptoms in males, while females are carriers because only one X chromosome is aff ected. The aim of this report is to show similarities and diff erences in clinical manifestations between twins with the L1CAM gene mutation and to emphasize the importance of genetic counseling. Our patients were dizygotic twins born prematurely at 35 weeks of gestation. Pregnancy was complicated with early bleeding and gestational diabetes. Immediately after birth, hypertonia of lower extremities was observed in both twins. Sixteen-year clinical follow up showed spastic paraparetic form with shuffl ing gait, clumsiness, delayed speech development, lower intellectual functioning at the level of mild to moderate mental retarda- tion, primary nocturnal enuresis, behavioral and sleep disorder (more pronounced in the second twin). Magnetic resonance imaging of the brain showed complete agenesis of the corpus callosum, complete lack of the anterior commissure, and internal hydrocephalus.
    [Show full text]
  • Level Estimates of Maternal Smoking and Nicotine Replacement Therapy During Pregnancy
    Using primary care data to assess population- level estimates of maternal smoking and nicotine replacement therapy during pregnancy Nafeesa Nooruddin Dhalwani BSc MSc Thesis submitted to the University of Nottingham for the degree of Doctor of Philosophy November 2014 ABSTRACT Background: Smoking in pregnancy is the most significant preventable cause of poor health outcomes for women and their babies and, therefore, is a major public health concern. In the UK there is a wide range of interventions and support for pregnant women who want to quit. One of these is nicotine replacement therapy (NRT) which has been widely available for retail purchase and prescribing to pregnant women since 2005. However, measures of NRT prescribing in pregnant women are scarce. These measures are vital to assess its usefulness in smoking cessation during pregnancy at a population level. Furthermore, evidence of NRT safety in pregnancy for the mother and child’s health so far is nebulous, with existing studies being small or using retrospectively reported exposures. Aims and Objectives: The main aim of this work was to assess population- level estimates of maternal smoking and NRT prescribing in pregnancy and the safety of NRT for both the mother and the child in the UK. Currently, the only population-level data on UK maternal smoking are from repeated cross-sectional surveys or routinely collected maternity data during pregnancy or at delivery. These obtain information at one point in time, and there are no population-level data on NRT use available. As a novel approach, therefore, this thesis used the routinely collected primary care data that are currently available for approximately 6% of the UK population and provide longitudinal/prospectively recorded information throughout pregnancy.
    [Show full text]
  • GENETIC TESTING REQUISITION Please Ship All
    GENETIC TESTING REQUISITION 1-844-363-4357· [email protected] Schillingallee 68 · 18057 Rostock Germany Attention Patient: Please visit your nearest LifeLabs or CML Healthcare Patient Service Centre for sample collection LL: K012-01/ CML: CEN CONTRACT # Report to Physician Billing # LifeLabs Demographic Ordering Physician Name Label Physician Signature: Ordering Physician Address: Tel: Fax: Address & Contact Info: Copy to (name & contact info): Name: Contact: Bill to Contract # K012-01 (patient does not pay at time of collection) Patient Gender: (M/F) Patient Name (Last, First): Patient DOB: (YYYY/MM/DD) Patient Address: Patient Health Card: Patient Telephone: Please ship all NON-PRENATAL samples to: LifeLabs · Attn CDS Department • 100 International Boulevard• Toronto ON• M9W6J6 TEST REQUESTED LL TR # / CML TC# □ Genetic Test - Blood Sample 2 x 4mL EDTA 4005 □ Genetic Test (Pediatric) - Blood Sample 1 x 2mL EDTA 4008 □ Genetic Test - Other Sample Type 4014 PRENATAL SAMPLES: Please ship directly to CENTOGENE. Date Blood Collected (YYYY/MM/DD): ___________ Time Blood Collected (HH:MM)) :________ Collector Name: ___________________ GENETIC TESTING CONSENT I understand that a DNA specimen will be sent to LifeLabs for genetic testing. My physician has told me about the condition(s) being tested and its genetic basis. I am aware that correct information about the relationships between my family members is important. I agree that my specimen and personal health information may be sent to Centogene AG at their lab in Germany (address below). To ensure accurate testing, I agree that the results of any genetic testing that I have had previously completed by Centogene AG may be shared with LifeLabs.
    [Show full text]
  • Orphanet Report Series Rare Diseases Collection
    Marche des Maladies Rares – Alliance Maladies Rares Orphanet Report Series Rare Diseases collection DecemberOctober 2013 2009 List of rare diseases and synonyms Listed in alphabetical order www.orpha.net 20102206 Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 289157 1-alpha-hydroxylase deficiency 309127 3-hydroxyacyl-CoA dehydrogenase 228384 5q14.3 microdeletion syndrome deficiency 293948 1p21.3 microdeletion syndrome 314655 5q31.3 microdeletion syndrome 939 3-hydroxyisobutyric aciduria 1606 1p36 deletion syndrome 228415 5q35 microduplication syndrome 2616 3M syndrome 250989 1q21.1 microdeletion syndrome 96125 6p subtelomeric deletion syndrome 2616 3-M syndrome 250994 1q21.1 microduplication syndrome 251046 6p22 microdeletion syndrome 293843 3MC syndrome 250999 1q41q42 microdeletion syndrome 96125 6p25 microdeletion syndrome 6 3-methylcrotonylglycinuria 250999 1q41-q42 microdeletion syndrome 99135 6-phosphogluconate dehydrogenase 67046 3-methylglutaconic aciduria type 1 deficiency 238769 1q44 microdeletion syndrome 111 3-methylglutaconic aciduria type 2 13 6-pyruvoyl-tetrahydropterin synthase 976 2,8 dihydroxyadenine urolithiasis deficiency 67047 3-methylglutaconic aciduria type 3 869 2A syndrome 75857 6q terminal deletion 67048 3-methylglutaconic aciduria type 4 79154 2-aminoadipic 2-oxoadipic aciduria 171829 6q16 deletion syndrome 66634 3-methylglutaconic aciduria type 5 19 2-hydroxyglutaric acidemia 251056 6q25 microdeletion syndrome 352328 3-methylglutaconic
    [Show full text]
  • Clinical and Genetic Characteristics and Prenatal Diagnosis of Patients
    Lin et al. Orphanet J Rare Dis (2020) 15:317 https://doi.org/10.1186/s13023-020-01599-y RESEARCH Open Access Clinical and genetic characteristics and prenatal diagnosis of patients presented GDD/ID with rare monogenic causes Liling Lin1, Ying Zhang1, Hong Pan1, Jingmin Wang2, Yu Qi1 and Yinan Ma1* Abstract Background: Global developmental delay/intellectual disability (GDD/ID), used to be named as mental retardation (MR), is one of the most common phenotypes in neurogenetic diseases. In this study, we described the diagnostic courses, clinical and genetic characteristics and prenatal diagnosis of a cohort with patients presented GDD/ID with monogenic causes, from the perspective of a tertiary genetic counseling and prenatal diagnostic center. Method: We retrospectively analyzed the diagnostic courses, clinical characteristics, and genetic spectrum of patients presented GDD/ID with rare monogenic causes. We also conducted a follow-up study on prenatal diagnosis in these families. Pathogenicity of variants was interpreted by molecular geneticists and clinicians according to the guidelines of the American College of Medical Genetics and Genomics (ACMG). Results: Among 81 patients with GDD/ID caused by rare monogenic variants it often took 0.5–4.5 years and 2–8 referrals to obtain genetic diagnoses. Devlopmental delay typically occurred before 3 years of age, and patients usu- ally presented severe to profound GDD/ID. The most common co-existing conditions were epilepsy (58%), micro- cephaly (21%) and facial anomalies (17%). In total, 111 pathogenic variants were found in 62 diferent genes among the 81 pedigrees, and 56 variants were novel. The most common inheritance patterns in this outbred Chinese popula- tion were autosomal dominant (AD; 47%), following autosomal recessive (AR; 37%), and X-linked (XL; 16%).
    [Show full text]